Sanofi and GSK Pursue Aggressive M&A Strategies Amid Challenges in mRNA Technology Funding and Tariffs

Sanofi and GSK have recently made significant moves in mergers and acquisitions (M&A), marking a notable shift in the pharmaceutical industry. Meanwhile, developments surrounding mRNA technology are facing challenges as changes in tariffs and funding emerge. Industry experts Jon Ellis and Simon Vanstone, PhD, analyzed these topics during a discussion on recent trends impacting the sector.

Ellis and Vanstone examined the implications of Sanofi and GSK’s aggressive M&A strategies, which signal potential shifts in market dynamics. They also addressed how adjustments to tariffs and funding mechanisms could influence the trajectory of mRNA technology, a field that gained prominence during the COVID-19 pandemic. The conversation highlighted key factors shaping these developments, including regulatory changes, financial pressures, and evolving priorities within global healthcare systems.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 4, 2025

Related posts:

Biosimilar Insulin Offers Potential Cost Relief: Several Products Approved or in Development Pharmacovigilance in Generic Drug Development: Prioritizing Safety Improves Reputation and Reduces Risks of Costly Recalls Researchers Identify Proteins and Pathways Influencing CAR-T Cell Therapy Effectiveness Against Blood Cancer Pharmaceutical Experts Highlight Hosted Content’s Role in Multichannel Strategies

Author

Mark Chiang